Evidence map›Paper›PMID 23185615›Full record

ArticlePloS one2012

Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1α.

Jonah R Riddell, Patricia Maier, Stephanie N Sass, Michael T Moser, Barbara A Foster, Sandra O Gollnick

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 77 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Food science & nutrition · 2023
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jonah R RiddellDepartment of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Patricia Maier
Stephanie N Sass
Michael T Moser
Barbara A Foster
Sandra O Gollnick
Roswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Christine B. Ambrosone · 1985 to 2026
$116.6M
Photodynamic Therapy (PDT) Mechanisms: Tumor ImmunityR01CA098156 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GOLLNICK, SANDRA O. · 2003 to 2013
$3.6M
Vitamin D Analogs for Chemoprevention of Prostate CAncerR01CA095367 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI FOSTER, BARBARA A. · 2002 to 2012
$3.2M
Prx1 in malignant progression of prostate cancerR01CA111846 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI JOHNSON, CANDACE S · 2006 to 2010
$1.5M
Peroxiredoxin 1 in radiotherapy of lung cancerR01CA109480 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI PARK, YOUNG-MEE · 2004 to 2007
$995k
NCI NIH HHS CA095367NCI NIH HHS CA109480NCI NIH HHS CA111846NCI NIH HHS CA16056NCI NIH HHS CA98156NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA095367NCI NIH HHS R01 CA098156NCI NIH HHS R01 CA109480NCI NIH HHS R01 CA111846
6 · The paper itself

Abstract

Chronic inflammation leads to the formation of a pro-tumorigenic microenvironment that can promote tumor development, growth and differentiation through augmentation of tumor angiogenesis. Prostate cancer (CaP) risk and prognosis are adversely correlated with a number of inflammatory and angiogenic mediators, including Toll-like receptors (TLRs), NF-κB and vascular endothelial growth factor (VEGF). Peroxiredoxin 1 (Prx1) was recently identified as an endogenous ligand for TLR4 that is secreted from CaP cells and promotes inflammation. Inhibition of Prx1 by CaP cells resulted in reduced expression of VEGF, diminished tumor vasculature and retarded tumor growth. The mechanism by which Prx1 regulates VEGF expression in normoxic conditions was investigated in the current study. Our results show that incubation of mouse vascular endothelial cells with recombinant Prx1 caused increases in VEGF expression that was dependent upon TLR4 and required hypoxia inducible factor-1 (HIF-1) interaction with the VEGF promoter. The induction of VEGF was also dependent upon NF-κB; however, NF-κB interaction with the VEGF promoter was not required for Prx1 induction of VEGF suggesting that NF-κB was acting indirectly to induce VEGF expression. The results presented here show that Prx1 stimulation increased NF-κB interaction with the HIF-1α promoter, leading to enhanced promoter activity and increases in HIF-1α mRNA levels, as well as augmented HIF-1 activity that resulted in VEGF expression. Prx1 induced HIF-1 also promoted NF-κB activity, suggesting the presence of a positive feedback loop that has the potential to perpetuate Prx1 induction of angiogenesis. Strikingly, inhibition of Prx1 expression in CaP was accompanied with reduced expression of HIF-1α. The combined findings of the current study and our previous study suggest that Prx1 interaction with TLR4 promotes CaP growth potentially through chronic activation of tumor angiogenesis.

Indexed as

AnimalsCell Line, TumorEndothelium, VascularGene Expression RegulationHomeodomain ProteinsHumansHuman Umbilical Vein Endothelial CellsHypoxia-Inducible Factor 1, alpha SubunitMaleMiceMice, SCIDNeoplasm TransplantationNeovascularization, PathologicNF-kappa BPromoter Regions, GeneticProstatic NeoplasmsHif1a protein, mouseHomeodomain ProteinsHypoxia-Inducible Factor 1, alpha SubunitNF-kappa BPrrx1 protein, mouseRNA, Small InterferingTlr4 protein, mouseToll-Like Receptor 4Vascular Endothelial Growth Factor Avascular endothelial growth factor A, mouse

Identifiers

PMID23185615
PMCPMC3503895
OpenAlexW2053120023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.